Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

ADVM-022 Intravitreal Gene Therapy for DME

ClinicalTrials.gov ID: NCT04418427

Public ClinicalTrials.gov record NCT04418427. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multi-Center, Randomized, Double-Masked, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects With Diabetic Macular Edema [INFINITY]

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Phase 2, Multi-Center, Randomized, Double-Masked\*, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects with Diabetic Macular Edema \[INFINITY\]

Study identification

NCT ID
NCT04418427
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Enrollment
36 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 28, 2020 (Actual)
Primary completion
Nov 22, 2022 (Actual)
Completion
Jun 14, 2023 (Actual)
Last update posted
Jul 10, 2025

2020 – 2023

United States locations

U.S. sites
13
U.S. states
9
U.S. cities
13
Facility City State ZIP Site status
Adverum Clinical Site Phoenix Arizona 85014 —
Adverum Clinical Site Bakersfield California 93309 —
Adverum Clinical Site Beverly Hills California 90211 —
Adverum Clinical Site Golden Colorado 80401 —
Adverum Clinical Site Deerfield Beach Florida 33064 —
Adverum Clinical Site Reno Nevada 89502 —
Adverum Clinical Site Philadelphia Pennsylvania 19107 —
Adverum Clinical Site West Columbia South Carolina 29169 —
Adverum Clinical Site Nashville Tennessee 37203 —
Adverum Clinical Site Abilene Texas 79606 —
Adverum Clinical Site Austin Texas 78705 —
Adverum Clinical Site Houston Texas 77030 —
Adverum Clinical Site The Woodlands Texas 77384 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04418427, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 10, 2025 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04418427 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →